- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02329756
Tranexamic Acid in Adherent Placenta (TAP)
Tranexamic Acid in Adherent Placenta (TAP), a Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in women undergoing cesarean-hysterectomy for suspected MAP. Subgroup analyses will be performed for laboratory results (coagulation studies, electrolytes, complete blood count), urine output, hemodynamic parameters, return to OR for continued bleeding, post-operative complications (thromboembolism, wound separation, infection, fever), and length of hospital stay. Eligible patients will be randomized to receive either TXA or placebo.
Women eligible for inclusion will be identified during their prenatal course or on admission to the hospital prior to surgery. They will be offered participation in the study after appropriate counseling regarding the equipoise regarding TXA and its use in pregnancy, and following a question and answer period they will be consented, and assigned a study number.
A randomization table will be generated by the Texas Children's Hospital Investigational Pharmacy, using balanced blocks of 8, and will maintain control of the randomization to ensure blinding of participants and the clinical investigators. Randomization will occur when an order for study medication will be sent on a paper requisition to the Texas Children's Hospital Investigational Pharmacy, and a randomization number will be assigned to correspond to the study number. Ideally, this order will be sumbitted 24h prior to scheduled surgery, but may be submitted for urgent cases by calling the Texas Children's Clinical Pharmacy, and delivering the paper requisition to the 7th Floor Main Pharmacy.
The Investigational Pharmacy will prepare study medication (Tranexamic acid I.V. or Normal saline as placebo) as determined by the randomization. The medication (whether study medication or placebo) will be packaged in identical syringes. Sealed, opaque envelopes will be available to the PI or an assigned designee to permit unblinding (linking randomization number and study number) only in the event of a clinical emergency involving a study partipant during times at which the Investigational Pharmacy is closed (nights, weekends, holidays).
Once a patient has been randomized, the outcome in hospital will be collected even if the study medication is interrupted or not actually given.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ultrasound and/or MRI diagnosed MAPL pregnancy scheduled to have a cesarean hysterectomy
- The responsible clinician is substantially uncertain as to whether or not to use TXA
- Consent has been given according to approved procedures
Exclusion Criteria:
- Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomized
- Prior known thromboembolic event during pregnancy
- Known contraindication to TXA (prior adverse reaction)
- Patient unable to give adequate consent due to emergent cesarean hysterectomy
- Bleeding prior to incision
- Prior known thromboembolic event
- Women with a history of any acute venous or arterial thrombosis including retinal artery/retinal vein occlusion, cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism
- History of decreased renal function, renal cortical disease, or significant renal tract disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
|
1g Tranexamic Acid (TXA) will be given at the time of delivery.
If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
Other Names:
|
Placebo Comparator: Control
Matching placebo (sodium chloride 0.9%) will be compared with treatment group
|
Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute. The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated blood loss (EBL)
Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
Our data from the past 65 cases of MAPL performed by our team over the past 3 years shows a 2500 +/- 500ml mean blood loss with these surgeries.
Using pooled estimates of the reduction in blood loss published in the literature, a 30% reduction is a reasonable expectation.
|
At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
Blood product requirements
Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
The administration of a fixed dose is more practicable in this study and we have thus selected a fixed dose of 1 gram of TXA 10 minutes prior to induction of anesthesia, followed by a second dose of 1 gram if heavy bleeding is encountered 30 or more minutes after starting the cesarean section which requires the transfusion of 4 or more units of blood products.
This is within the dose range which has been shown to inhibit fibrinolysis and provide hemostatic benefit.
|
At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
Hemoglobin level change post surgery
Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
The level of hemoglobin change will be measured after surgery.
|
At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thromboembolic events
Time Frame: From time patient is given treatment up to 12 weeks post-partum.
|
Data from all thromboembolic events will be documented on CRFs, including but not limited to the amount and severity of events.
|
From time patient is given treatment up to 12 weeks post-partum.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael A Belfort, MD, PhD, Baylor College of Medicine
- Principal Investigator: Karin A Fox, MD,MEd, Baylor College of Medicine
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-41847 (Other Identifier: Baylor College of Medicine Institutional Review Board)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Placenta Accreta
-
Kasr El Aini HospitalUnknownPlacenta Accreta in Placenta Previa Anterior
-
Ain Shams Maternity HospitalCompleted
-
Maternal and Child Health Hospital of FoshanWithdrawnPlacenta Accreta SpectrumChina
-
Sohag UniversityRecruiting
-
Necmettin Erbakan UniversityRecruitingPlacenta Accreta, Third TrimesterTurkey
-
Ain Shams UniversityNot yet recruiting
-
Ain Shams UniversityUnknownPlacenta Accreta, Third TrimesterEgypt
-
HaEmek Medical Center, IsraelTechnion, Israel Institute of TechnologyUnknown
-
Hatem AbuHashimCompletedPlacenta Accreta SpectrumEgypt
-
Hatem AbuHashimUnknownPlacenta Accreta Spectrum
Clinical Trials on Tranexamic Acid (TXA)
-
HaEmek Medical Center, IsraelWithdrawn
-
Rush University Medical CenterWithdrawnArthritis | Anemia | Total Knee Arthroplasty | Total Hip ArthroplastyUnited States
-
Boston Children's HospitalCompletedCraniosynostosisUnited States
-
NYU Langone HealthTerminated
-
Mansoura UniversityNot yet recruiting
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Cristina MartinezCompleted
-
Rush University Medical CenterCompletedBlood Loss After Primary Total Joint Arthroplasty | Need for Blood Transfusion After Total Joint ArthroplastyUnited States
-
University of Kansas Medical CenterCompletedSarcoma,Soft Tissue | Musculoskeletal CancerUnited States
-
NYU Langone HealthCompletedTibial Tubercle OsteotomyUnited States